PDCD1 and non-small cell lung carcinoma: In recent years, the development and application of immune checkpoint inhibitors (ICIs), including programmed cell death protein 1 (PD-1) antibody, programmed death ligand 1 (PD-L1) antibody, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, have provided significant survival benefits for patients with wild-type advanced NSCLC.